Results 91 to 100 of about 12,722 (192)

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources

Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction [PDF]

, 2020
Objectives: The authors sought to evaluate the prognostic significance of baseline N-terminal pro–B-type natriuretic peptide (NT-proBNP), whether NT-proBNP modified the treatment response to sacubitril/valsartan, and the treatment effect of sacubitril ...
Anand, Inder S., Chopra, Vijay K., Claggett, Brian L., Cunningham, Jonathan W., Janssens, Stefan, Jhund, Pardeep S., Kober, Lars, Lam, Carolyn S.P., Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Pfeffer, Marc A., Prescott, Margaret F., Rouleau, Jean, Shah, Sanjiv J., Shi, Victor C., Solomon, Scott D., Vaduganathan, Muthiah, Zannad, Faiez, Zile, Michael R.   +19 more
core   +3 more sources

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, EarlyView.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

Novel Isocratic HPLC Method for Simultaneous Estimation of Sacubitril and Valsartan in Bulk and Formulation [PDF]

Brazilian Archives of Biology and Technology
In compliance with ICH requirements, a new selective, precise, and accurate reverse-phase High-Performance Liquid Chromatographic method for valsartan and sacubitril quantification was developed and validated. Eluents were detected at 284 nm.
Harshavardhan Rajendra Karnik, Ambar Bhikasaheb Marne, Ashwin Bhanudas Kuchekar, Ashwini Ramkrishna Gawade   +3 more
doaj   +1 more source

Declining risk of sudden death in heart failure [PDF]

, 2017
No abstract ...
Jhund, Pardeep S., McMurray, John J.V., Shen, Li   +2 more
core   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
Sacubitril/Valsartan (Sac/Val) alleviates fibrosis and inflammation in metabolic dysfunction‐associated steatohepatitis (MASH). Its anti‐fibrotic effect is linked to the suppression of Integrin alpha 8 (Itga8), a protein crucial for hepatic stellate cell (HSC) activation and collagen production.
Hayato Kawamura, Aya Naiki‐Ito, Xiaochen Kuang, Akihiro Murakami, Masayuki Komura, Takanori Suzuki, Hiroyuki Kato, Yuko Nagayasu, Kentaro Matsuura, Kei Fujiwara, Hiromi Kataoka, Satoru Takahashi   +11 more
wiley   +1 more source

Sacubitril/Valsartan (EntrestoTM) hospital prescribing in patients with symptomatic chronic HF with reduced ejection fraction:a UK multi-centre study [PDF]

, 2019
Background:Sacubitril/valsartan is a combination drug therapy for heart failure (HF) patients that has been shown to reduce mortality and hospitalisation.Aims:To explore clinically relevant real-life patient data regarding prescribing of sacubitril ...
Cabdi, Summaya, Dorsch, Marina, Gill, Navneet K., Jalal, Zahraa, Jones, Alan M, Khan, Nazish, Toner, Fionnuala   +6 more
core   +1 more source

Establishment of a mouse model for ischaemic heart failure induced by coronary microembolization via left ventricular oil injection

Experimental Physiology, EarlyView.
Abstract Over the past three decades, there has been a steady increase in clinical attention to ischaemic heart failure caused by coronary microembolization. Nonetheless, a suitable mouse model for studying this condition remains limited. In the present study, we developed a mouse model of coronary microembolization‐induced ischaemic heart failure by ...
Lang Pei, Yusheng Hong, Qiuyue Wu, Jianyi Lv, Changlong Li, Xueyun Huo, Xin Liu, Di Zhang, Meng Guo, Zhenwen Chen, Xiaoyan Du   +10 more
wiley   +1 more source